Literature DB >> 16039892

A brief review of the use and utility of growth hormone stimulation testing in the NCGS: do we need to do provocative GH testing?

Darrell M Wilson1, James Frane.   

Abstract

True growth hormone deficiency (GHD) in childhood, while rare, has major clinical consequences. GHD is often associated with other pituitary hormone deficiencies, so these children may require multiple hormonal replacement and close clinical follow-up to optimize their outcome. Growth hormone stimulation testing (GHST), as currently conducted, is not a reliable diagnostic tool. Both changes in growth hormone assay methodologies and increases in the diagnostic threshold contribute to the incorrect labeling of a substantial proportion of normal children as having idiopathic GHD. Fortunately, newer imaging technologies and laboratory tests form a more rational basis to diagnose true GHD. The use of GHST among GH-naive subjects (<20 years of age) enrolled in the National Cooperative Growth Study has declined over the past two decades, from a high of 89% between 1987 and 1989 to only 52% in 2002. Given that GH stimulation testing does not meaningfully aid in distinguishing those few children with true growth hormone deficiency from the much more common short normal child and that alternatives are now available, it is time to discontinue the routine use of GHST in children.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16039892     DOI: 10.1016/j.ghir.2005.06.005

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  5 in total

1.  Endocrine Deficiency As a Function of Radiation Dose to the Hypothalamus and Pituitary in Pediatric and Young Adult Patients With Brain Tumors.

Authors:  Ralph E Vatner; Andrzej Niemierko; Madhusmita Misra; Elizabeth A Weyman; Claire P Goebel; David H Ebb; Robin M Jones; Mary S Huang; Anita Mahajan; David R Grosshans; Arnold C Paulino; Takara Stanley; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock
Journal:  J Clin Oncol       Date:  2018-08-17       Impact factor: 44.544

2.  Diagnosis of growth hormone (GH) deficiency: comparison of pituitary stalk interruption syndrome and transient GH deficiency.

Authors:  Murielle Louvel; Mariana Marcu; Christine Trivin; Jean-Claude Souberbielle; Raja Brauner
Journal:  BMC Pediatr       Date:  2009-05-06       Impact factor: 2.125

3.  Influence of biochemical diagnosis of growth hormone deficiency on replacement therapy response and retesting results at adult height.

Authors:  Giulia Rodari; E Profka; F Giacchetti; I Cavenaghi; M Arosio; C Giavoli
Journal:  Sci Rep       Date:  2021-07-15       Impact factor: 4.379

4.  Selecting short-statured children needing growth hormone testing: derivation and validation of a clinical decision rule.

Authors:  Laëtitia Duché; Christine Trivin; Wassim Chemaitilly; Jean Claude Souberbielle; Gérard Bréart; Raja Brauner; Martin Chalumeau
Journal:  BMC Pediatr       Date:  2008-07-16       Impact factor: 2.125

5.  Efficacy and safety of Samtropin™ recombinant human growth hormone; a double-blind randomized clinical trial.

Authors:  Ozra Tabatabaei-Malazy; Mohammad Reza Mohajeri-Tehrani; Ramin Heshmat; Eghbal Taheri; Gita Shafiee; Maryam Razzaghy-Azar; Ali Rabbani; Mostafa Qorbani; Hossein Adibi; Samimeh Shahbazi; Farzaneh Karimi; Sheema Rezaian; Bagher Larijani
Journal:  J Diabetes Metab Disord       Date:  2014-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.